Here's why this ASX 200 healthcare share is racing 5% higher

This ASX 200 healthcare share is charging higher today…

The Ramsay Health Care Limited (ASX: RHC) share price is ending the week on a high.

In afternoon trade, the private hospital operator's shares are beating the ASX 200 index with a 5% gain to $62.02.

A doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

Why is the Ramsay share price beating the ASX 200?

Investors have been bidding the Ramsay share price higher on Friday following the release of the company's first quarter update.

According to the release, activity levels improved across all regions over the quarter compared to the prior corresponding period. Management advised that this reflects the decline in COVID cases in the community.

In light of this, the COVID impact on its profits in Australia and the UK fell from $44 million in July to just $5.9 million in September. The total impact across the quarter in these markets is estimated to have been $64.4 million.

Ramsay also revealed that it has been fighting rising costs. It advised that it is focused on negotiating improved terms with payors to reflect higher staffing costs related to labour shortages and inflationary pressures. Management notes that it finalised satisfactory new agreements with a number of private payors over the quarter.

This ultimately led to Ramsay reporting a 6.7% increase in revenue to $3,445.4 million and a 2.3% decline in EBITDA to $410.6 million for the first quarter.

Outlook

Pleasingly, this momentum has carried over into October, with Ramsay starting the second quarter positively. Looking ahead, management appears optimistic that it is onwards and upwards from here.

It commented:

The outlook for the Group remains strong as the business is well placed to take advantage of the positive long-term dynamics driving the healthcare industry. Ramsay expects a gradual recovery through FY23 and more normalised conditions from FY24.

The Ramsay share price remains down 13.5% in 2022 despite today's decline.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Happy healthcare workers in a lab.
Healthcare Shares

Mesoblast reports Ryoncil revenue surge and improved cash spend

Mesoblast reported a 44% jump in Ryoncil revenue and a substantial improvement in operating cash spend.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Down 44%: Will you regret not buying Pro Medicus shares?

The shares have fallen hard, but the business itself continues to grow at an impressive rate.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

CSL shares: Buy, hold, or sell?

The shares have recovered sharply, so I wanted to see whether the valuation still stacks up.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »